Phase 3 N=148 DE-111 Ophthalmic Solution in Patients With Open Angle Glaucoma or Ocular Hypertension
Open Angle Glaucoma or Ocular Hypertension
Primary: Change From Baseline in IOP (Intraocular Pressure) at End of Study — -1.8 mmHg
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=1,553 A Study of GANFORT® UD in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) in a Medical Setting
Glaucoma, Primary Open Angle · Ocular Hypertension
Primary: Change From Baseline in Intraocular Pressure (IOP) in the Study Eye — 22.18; 16.11 mmHg
Phase 4 N=35 Peripapillary Blood Flow After Use of Anti-glaucoma Medications: An OCT Angiography Study
Glaucoma; Drugs · Normal Tension Glaucoma · Primary Open-angle Glaucoma
Primary: Changes in Vessel Density in Treatment Groups Assessed by OCT Angiography — -0.51; 2.59; -0.96; 0.96 percent change
N/A N=4,812 A Study of Intraocular Pressure (IOP) Reduction in Newly Diagnosed Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
Glaucoma, Open-Angle · Ocular Hypertension
Primary: Percentage of Patients With a Reduction in Intraocular Pressure (IOP) ≥ 5mmHg From Baseline — 75.9 Millimeters of Mercury (mmHg)
N/A N=392 GANfort® in Patients With Primary Open Angle Glaucoma or Ocular Hypertension Who Are Insufficiently Responsive to Monotherapy
Glaucoma, Open-Angle · Ocular Hypertension
Primary: Change From Baseline in Intraocular Pressure (IOP) — 22.0; -6.0; 22.0; -6.0 Millimeters of Mercury (mmHg)
N/A N=854 Lumigan® in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
Glaucoma, Open-Angle · Ocular Hypertension
Primary: Change From Baseline in Intraocular Pressure (IOP) — 19.0; -4.0; 20.0; -5.0 Millimeters of Mercury (mmHg)
N/A N=358 An Observational Study of Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) Who Switched IOP-lowering Treatments
Glaucoma, Open-Angle · Ocular Hypertension
Primary: Change From Baseline in Intraocular Pressure (IOP) in the Right Eye — -4.5 mmHg
Phase 2 N=47 Safety and Efficacy of a Drug Delivery System in Glaucoma
Open-angle Glaucoma · Ocular Hypertension
Primary: Mean Change in Intraocular Pressure at Day 1 — -4.16; -4.57; -0.60 mmHg
N/A N=102 Study Comparing Quantitative Assessments in Open-angle Glaucoma (OAG) and/or Ocular Hypertension (OHT)
Glaucoma, Open-Angle · Ocular Hypertension
Primary: Intra- Examiner Agreement in Angle Width by Goniometric Lens — 0.88 Kappa statistics
Phase 2 N=172 Safety and Efficacy of AGN 210669 Ophthalmic Solution in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma
Ocular Hypertension · Glaucoma
Primary: Change From Baseline in Average Eye Intraocular Pressure (IOP) — 25.350; 25.318; 25.341; 24.650 Millimeters of Mercury (mmHg)
N/A N=10,337 A Study of Lumigan® in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
Glaucoma, Open-Angle · Ocular Hypertension
Primary: Change From Baseline in Intraocular Pressure (IOP) — 20.0; -4.0; 20.0; -4.0 Millimeters of Mercury (mmHg)
Phase 2 N=241 A Phase IIb Safety and Efficacy Study of DE-126 Ophthalmic Solution in Primary Open-Angle Glaucoma or Ocular Hypertension- Angel Study
Open-angle Glaucoma, Ocular Hypertension
Primary: Intraocular Pressure in the Study Eye at Month 3 — 18.8; 18.1; 19.7; 19.2 mmHg
N/A N=7 Effect of Cosopt Versus Combigan on Retinal Vascular Autoregulation in Primary Open Angle Glaucoma (POAG)
Glaucoma
Primary: Presence of Retinal Vascular Dysregulation (RVD) — 7; 4 Participants
Phase 2 N=125 Safety and Efficacy of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension
Glaucoma, Open-Angle · Ocular Hypertension
Primary: Change From Baseline in Average Eye IOP — 26.16; 25.98; 26.26; 23.91 Millimeters of Mercury (mmHg)
N/A N=33 Analysis of the Eye in Patients With Primary Open-Angle Glaucoma and a Visual Field Defect in One Eye
Glaucoma
Primary: Lamina Cribrosa (Boundaries of the Retinal Layers) Measurements — 264.3; 273.3; 276.2 micro-ohms
N/A N=16 Effect of Travoprost 0.004% on Retinal Oximetry in Primary Open Angle Glaucoma
Primary Open Angle Glaucoma
Primary: Blood Oxygenation — 60; 60; 60 percentage of oxygenation
Phase 4 N=87 A Study of 0.03% Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension
Glaucoma, Open-Angle · Ocular Hypertension
Primary: Change From Baseline in Intraocular Pressure (IOP) in the Study Eye — 22.2; -6.7 Millimeters of Mercury (mmHg)
Phase 4 N=376 A Study of 0.15% Brimonidine Tartrate in Patients With Primary Open Angle Glaucoma and Ocular Hypertension
Glaucoma, Open-Angle · Ocular Hypertension
Primary: Change From Baseline in Intraocular Pressure (IOP) in the Study Eye — 25.4; -6.3 Millimeters of Mercury (mmHg)
Phase 4 N=263 A Study of Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension
Glaucoma, Open-Angle · Ocular Hypertension
Primary: Intraocular Pressure (IOP) in the Study Eye — 16.5; 16.7; 15.7; 16.1 Millimeters of Mercury (mmHg)
Phase 2 N=55 Safety and Efficacy of a Glaucoma Drug Delivery System
Glaucoma, Open-Angle · Ocular Hypertension
Primary: Visual Acuity - Right Eye — 0.015; -0.044; -0.012 logMAR units
N/A N=387 Observational Study of Lumigan® 0.01% Treatment for Patients With Primary Open Angle Glaucoma or Ocular Hypertension
Glaucoma, Open-Angle · Ocular Hypertension
Primary: Intraocular Pressure (IOP) at Baseline — 22.0; 22.0 mm Hg
Phase 3 N=1,636 Ocular Hypertension Treatment Study (OHTS)
Ocular Hypertension · Glaucoma
Primary: Incidence of Primary Open-Angle Glaucoma in Hypotensive Patients — 9.5; 4.4; 20.0; 14.1 percent of participants
N/A N=902 Observational Study of the Long-term Effect of Latanoprost in Normal Tension Glaucoma
Low Tension Glaucoma
Primary: Change From Baseline in Raw Intraocular Pressure (IOP) by Visit — -3.20; -3.12; -3.22; -3.43 mmHg
Phase 4 N=121 Glaucoma Biomarkers
Glaucoma · Healthy
Primary: Variation in Eye Pressure Between Individuals. — 11.5; 11.3; 11.0; 11.0 mmHg — p=0.0001
Phase 1 N=50 Safety and Pharmacodynamics Study of AGN-207281 Ophthalmic Solutions Compared With Timolol Ophthalmic Solution or Placebo in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma
Glaucoma, Open-Angle · Ocular Hypertension
Primary: Change From Baseline in Worse Eye Intraocular Pressure (IOP) at Day 14 — 25.98; 26.58; 26.45; 25.93 Millimeters of mercury (mm Hg)
N/A N=419 A Study of Lumigan® 0.01% in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
Glaucoma, Open-Angle · Ocular Hypertension
Primary: Intraocular Pressure (IOP) at Baseline — 21.23; 21.38 Millimeters of Mercury (mmHg)
Phase 3 N=447 To Compare the Efficacy and Safety of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes
Glaucoma, Open-Angle · Ocular Hypertension
Primary: Mean Change in Intra-ocular Pressure — -5.30; -5.16; -6.92; -6.57 mmHG
Phase 3 N=161 Evaluation of Safety of SPARC0913 in Open Angle Glaucoma or Ocular Hypertension
Open Angle Glaucoma · Ocular Hypertension
Primary: Number of Subjects With AEs — 140 participants
N/A N=209 Study of OMNI System in OAG (GEMINI)
Open Angle Glaucoma
Primary: Change in Mean Unmedicated Diurnal IOP — 7.98 mm Hg
Phase 3 N=495 To Compare the Safety and Efficacy of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes
Glaucoma, Open-Angle · Ocular Hypertension
Primary: Mean Change in Intra-ocular Pressure — -4.25; -3.80; -4.22; -4.00 mmHG